Simulations Plus, Inc. - Common Stock (SLP)

Simulations Plus Inc. reported lower than expected sales and reduced guidance due to cautious biopharma spending.

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

U.S. stock futures were lower on Monday after ending on a negative note on Friday. Futures of major benchmark indices were lower.

US stock futures down, potential focus on Fastenal, FB Financial, Datavault AI's deal with IBM, Equity Bancshares, Simulations Plus earnings.

The CNN Business Fear & Greed Index showed a slight decline in market sentiment on Friday, while major indices closed lower.

SPB, SLP, and LUCK may offer a chance for investors to buy low; when market conditions improve, analysts expect these firms to rise.

Simulations Plus stock fell after it issued a weaker 2025 outlook and forecast Q3 revenue below expectations, citing biotech market pressures.

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.